Fox Chase Cancer Center News

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene — a gene that can cause cancer — that may play an important role in colon cancer. Researchers also showed how this mutation could be targeted therapeutically.

A pilot program developed to educate healthcare providers about patient chemosensory dysfunction significantly improved providers’ knowledge and confidence in providing support to patients, according to a recent publication on the program from clinicians and researchers at Fox Chase Cancer Center.

A new paper published by researchers at Fox Chase Cancer Center highlights the case of a patient who was diagnosed with adenoid cystic carcinoma (ACC) after a molecular panel identified the presence of an atypical fusion gene.

Physicians at Fox Chase Cancer Center have now performed 10,000 surgeries using the da Vinci robotic surgical system, which has been essential in expanding access to the latest treatment options for cancer patients across multiple cancer specialties.

Andrea Califano, Dr, a leader in the field of systems biology, was recognized today at Fox Chase Cancer Center with the Stanley P. Reimann Honor Award, the center’s highest distinction.

The Cancer Epigenetics Institute (CEI) at Fox Chase Cancer Center recently selected two graduate students for its inaugural Graduate Student Fellowship Awards.

New research by a Fox Chase Cancer Center physician shows that DIEP flap surgery is extremely safe, with a low rate of readmission and complications.

Patients with metastatic colorectal cancer who were treated with a biweekly dose of trifluridine-tipiracil (TAS-102) saw similar treatment effectiveness and reduced toxicity compared with treatment using standard dosing schedules, according to a recent study in The Oncologist that was co-authored by a Fox Chase Cancer Center physician.